The Canadian Foundation for Pharmacy is very proud to announce one of the winners of its annual Innovation Fund Grant: Dr. Barbara Farrell from the Bruyère Research Institute in Ottawa.
The “Mobilizing Community Pharmacists as Catalysts for Deprescribing” project aims to explore and build community pharmacists’ capacity to integrate deprescribing into their workflow.
Deprescribing refers to the reduction in dose or stopping of medication that may be causing more harm than benefit. It’s an important strategy to minimize the harm associated with polypharmacy.
The project will be based at the Bruyère Research Institute, under the leadership of Dr. Barbara Farrell who also led the innovative development of evidence-based deprescribing guidelines to assist clinicians in making decisions about deprescribing and then reducing or stopping medications safely.
“Pharmacists can play an important role in reducing polypharmacy through deprescribing of unnecessary medications. Dr. Farrell’s research will develop guidelines for pharmacists to support deprescribing and explore how pharmacists can be appropriately reimbursed for this important intervention”, states the Foundation’s President, Dr. David Edwards of the University of Waterloo.
“Our team will work with community pharmacy practices and a national Advisory Group (with pharmacy provider and private payor representation) over a one year period to develop acceptable workflow strategies for deprescribing guideline use,” offered lead investigator, Dr. Farrell. The team of investigators includes, Drs. James Conklin, Lisa Dolovich, Lisa McCarthy and Lalitha Raman-Wilms.
The Canadian Foundation for Pharmacy’s Innovation Fund has become a leading source of funding in Canada for evidence-based research evaluating the value of new services offered by pharmacists. Through its Innovation Fund, the foundation currently supports projects and research that facilitate the evolving role of the pharmacist. Since 2004, CFP has invested more than $1 million to this cause.